Aramchol companion diagnostic - Galmed Pharmaceuticals/One Way Liver Genomics

Drug Profile

Aramchol companion diagnostic - Galmed Pharmaceuticals/One Way Liver Genomics

Latest Information Update: 07 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Galmed Pharmaceuticals; One Way Liver Genomics
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis

Most Recent Events

  • 30 Jun 2016 Galmed Pharmaceuticals signs an optional licensing agreement with Yeda Research and Development for commercialisation of the companion diagnostic tool
  • 23 Jul 2015 Galmed Pharmaceuticals and One Way Liver Genomics plan a phase III trial for Non-alcohollic steatohepatitis (Diagnosis) in USA and Europe ,
  • 08 Jul 2015 Galmed Pharmaceuticals enters into a research, option, license and a share purchase agreement with One Way Liver Genomics for development of a companion diagnostic tool
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top